This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Einsele H, Bamberg M, Budach W et al. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplant 2003; 32: 593–599.
Attal M, Harousseau JL, Facon T et al. Single vs double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.
Corradini P, Voena C, Tarella C et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208–215.
Turner JH, Claringbold PG, Berger JD et al. Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: an experimental model in the rat. Nucl Med Commun 1992; 13: 321–329.
Parks NJ, Kawakami TG, Avila MJ et al. Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP). Blood 1993; 82: 318–325.
Bayouth JE, Macey DJ, Kasi LP et al. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med 1995; 36: 730–737.
Bartlett ML, Webb M, Durrant S et al. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. Eur J Nucl Med Mol Imaging 2002; 29: 1470–1477.
O'Sullivan JM, McCready VR, Flux G et al. High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 2002; 86: 1715–1720.
Giralt S, Bensinger W, Goodman M et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase I/II trials. Blood 2003; 102: 2684–2691.
Acknowledgements
We gratefully appreciate the support of Dr Dorothea Alber, Hahn-Meitner-Institute, SF6, Berlin, who was responsible for the production of the 186Re used.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wiesmann, A., Einsele, H., Kanz, L. et al. Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma. Bone Marrow Transplant 36, 89–90 (2005). https://doi.org/10.1038/sj.bmt.1705002
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705002